Clinical trial
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to…
NCT00417690 · Jacobus Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00417690 |
|---|---|
| Title | High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease |
| Official title | A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease |
| Lead sponsor | Jacobus Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | 4-Aminosalicylic acid, PASER placebo granules |
| Enrollment | 54 |
| Start date | Jan 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Jan 4, 2007 |
| Last update posted | Oct 15, 2008 |
| Countries | Israel, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: